Moderna, Inc., a provider of messenger RNA (mRNA) therapeutics and vaccines, entered into a long-term agreement with Ontario-based Novocol Pharma, a sterile injectable contract development and manufacturing organization (CDMO), to perform aseptic fill-finish, labelling and packaging of mRNA respiratory vaccines expected to be produced in Canada.
The agreement with Novocol Pharma will result in the fill-finish capacity of vaccines manufactured at Moderna’s Laval-based mRNA facility, which is expected to become operational by the end of 2024, subject to planning and regulatory approvals.
